Edition:
United States

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.63USD
18 May 2018
Change (% chg)

$0.20 (+14.39%)
Prev Close
$1.42
Open
$1.45
Day's High
$1.65
Day's Low
$1.41
Volume
316,093
Avg. Vol
64,465
52-wk High
$2.50
52-wk Low
$1.05

Chart for

About

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct... (more)

Overall

Beta: 0.42
Market Cap(Mil.): $66.75
Shares Outstanding(Mil.): 46.84
Dividend: --
Yield (%): --

Financials

  SCYX.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -0.86 -- --
ROI: -44.83 13.08 12.63
ROE: -68.75 14.80 14.50

BRIEF-Scynexis Q1 Loss Per Share $0.12

* SCYNEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

May 08 2018

BRIEF-Caxton Corporation Reports 9.99 Percent Passive Stake In Scynexis Inc As Of March 6, 2018 - SEC Filing‍​

* CAXTON CORPORATION REPORTS 9.99 PERCENT PASSIVE STAKE IN SCYNEXIS INC AS OF MARCH 6, 2018 - SEC FILING‍​ Source text (http://bit.ly/2tII9WD) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 13 2018

BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants

* SCYNEXIS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

Mar 06 2018

BRIEF-Scynexis Inc Presents New In Vivo Data Highlighting The Potential Of Scy-078

* SCYNEXIS PRESENTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF SCY-078 USED IN COMBINATION FOR THE TREATMENT OF ASPERGILLUS INFECTIONS AT AAA 2018 Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​

Jan 04 2018

Earnings vs. Estimates